PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
PHAXIAM Therapeutics and Vetophage Announce
- Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy
- Combining expertise in the research of new phages and phage endolysins that could be applied to human health
- Exclusive phage and endolysin licensing options in human health for PHAXIAM Therapeutics
Lyon (France) and Cambridge (MA, US), October03, 2023 – 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) and Vetophage, a company specialized in phage therapy applied to animal health, announce the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance.
Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages and endolysins to tackle antimicrobial resistance in animals.
Through its innovative technological platform, Vetophage benefits from a wide range of capabilities for the discovery, identification and characterization of phages and endolysins. The company enables PHAXIAM Therapeutics to screen its broad phage and endolysin bank targeting highly antimicrobial-resistant infections.
This agreement gives PHAXIAM Therapeutics exclusive licensing options on specified phages and endolysins in human health from the Vetophage platform, to further strengthen its product portfolio. This strategic partnership initiates the potential for future research and industrial collaborations that will capitalize on PHAXIAM's expertise, while strengthening its development program dedicated to the fight against antimicrobial resistance.
« The agreement with Vetophage is a significant milestone for PHAXIAM Therapeutics' development in the fight against severe resistant infections. We take a long-standing interest in the work carried out by the Vetophage teams, and we are delighted to collaborate with such a recognized player in the veterinary field to build bridges between phage therapy in animal health and for humans, the OneHealth approach being at the heart of today's healthcare strategies», said Thibaut Du Fayet, Chief Executive Officer of PHAXIAM Therapeutics. « This partnership reinforces our phage expertise and strengthens our competitive position in this field, enabling us to rapidly expand our phage portfolio for our most strategic programs. It also enables us to rapidly penetrate the technological field of endolysins, which are highly complementary to phages in our clinical applications. »
Mai-Huong Chatain, President of Vetophage, adds: « This new long-term agreement confirms the relevanceof our strategy and the value of our bacteriophage expertise. The potential synergies between the infrastructure developed by PHAXIAM Therapeutics and our own technological platform are significant and will enable us to capitalize on our common knowledge of phage therapy to develop innovative treatments as quickly as possible, and thus fight antimicrobial-resistant infections in humans and animals. »
Florence Agostino-Etchetto, Chief Executive Officer of Lyonbiopôle, concludes: « I'm particularly proud of this collaboration between two Lyon-based biotech companies, both members of the Lyonbiopôle cluster and pioneers in their respective fields. This partnership, structured around the fight against antimicrobial resistance, a critical public health issue recognized worldwide, is an illustration of the dynamism and advanced level of maturity of our regional ecosystem around infectious diseases, in which our members are particularly involved. I am convinced that this partnership will contribute to the development of the French phage therapy industry, now recognized as a strategic and sovereign technology at the European level. »
Vetophage is an innovative company dedicated to the research and development of innovative solutions in the field of veterinary biotechnology. Founded in 2017, located in Saint-Priest (Lyon region) and with a team of 10 highly specialized employees, Vetophage leverages strong skills on the use of phages and phage-derived proteins to fight bacterial diseases in animals. Its technological platform is used to develop therapeutic and detection tools for animal health.
For further information, visit www.vetophage.fr
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
COO & CFO
+33 4 78 74 44 38
Mathilde Bohin / Dušan Orešanský
+33 1 44 71 94 94
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Canada Carbon Provides Update on Its Asbury Mine Exploration Program1.12.2023 04:04:42 CET | Press release
TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Canada Carbon Inc. (the "Company" or "Canada Carbon” or ("CCB"), (TSX-V:CCB), (FF:U7N1) is pleased to report that extensive graphitic mineralization was observed during its ongoing drill program on the Asbury Property (“the Property”). The Company would like to take this opportunity to provide a general update regarding the exploration program on the Property. Current exploration work includes drilling, completion of an NI 43-101 compliant resource calculation, metallurgical testing and development of a geochemical signature. The information provided from the exploration work will allow the Company to proceed with a Preliminary Economic Study to be completed in 2024. Drill Program Phase 1 of the drill program commenced on October 16th, and will be completed on November 30th 2023. The current drill program is testing a folded conductor anomaly, located on the North Eastern side of a regional magnetic anomaly. The drilled area is mostly located
Delårsrapport januari – september 202330.11.2023 23:59:00 CET | Pressemelding
Tredje kvartalet 2023 (jämfört med tredje kvartalet 2022) Nettoomsättningen uppgick till 8 MSEK (24)Bruttomarginalen ökade till 67 % (35 %)Rörelseresultatet ökade till 128 MSEK (-14)Periodens nettoresultat blev 122 MSEK (-4)Resultat per aktie före och efter utspädning ökade till 0,45 SEK (-0,05) Januari – september 2023 (jämfört med januari – september 2022) Nettoomsättningen uppgick till 30 MSEK (61)Bruttomarginalen ökade till 66 % (63 %)Rörelseresultatet ökade till 98 MSEK (-37)Nettoresultatet blev positivt och uppgick till 99 MSEK (-9)Resultat per aktie före och efter utspädning uppgick till 0,42 SEK (-0,17) Rapporten för januari – september 2023 i sin helhet finns tillgänglig på följande adress: https://www.anoto.com/investors/reports/ För ytterligare information kontakta: Joonhee Won, VD, Anoto Group AB För mer information om Anoto, besök www.anoto.com eller email email@example.com Denna information är sådan information som Anoto Group AB (publ) är skyldigt att offentliggöra enligt EU:
Interim Report January – September 202330.11.2023 23:59:00 CET | Press release
Third quarter 2023 (compared to third quarter 2022) Net sales for the quarter amounted to MSEK 8 (24)Gross margin for the quarter increased to 67% (35%)Operating profit increased to MSEK 128 (-14)Net income for the period turned to profit of MSEK 122 (-4)Earnings per share before and after dilution increased to SEK 0.45 (-0.05) January – September 2023 (compared to January – September 2022) Net sales for the period amounted to MSEK 30 (61)Gross margin for the period increased to 66% (63%)Operating profits increased to MSEK 98 (-37)Net income became positive at MSEK 99 (-9)Earnings per share before and after dilution increased to SEK 0.42 (-0.17) The report for January – September 2023 is available in its entirety on the following address: https://www.anoto.com/investors/reports/ For further information, please contact: Joonhee Won, CEO, Anoto Group AB For more information about Anoto, please visit www.anoto.com or email firstname.lastname@example.org This information is information that Anoto Group AB (
Tenaris Completes Acquisition of Pipe Coating Business Unit of Mattr30.11.2023 23:06:23 CET | Press release
LUXEMBOURG, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced that it has completed today the acquisition from Mattr (MATR.TO) of Mattr’s pipe coating business unit for US$182.6 million (including estimated working capital and US$16.9 million in cash). The business acquired includes nine plants located in Canada, Mexico, Norway, Indonesia, the UAE and the US, and several mobile concrete plants. The business also includes world-class R&D facilities in Canada and Norway and a wide IP/product portfolio. Some of the statements contained in this press release are “forward-looking statements”. Forward-looking statements are based on management’s current views and assumptions and involve known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied by those statements. These risks include but are not limited to risks arising from uncertainties as to future oil and gas prices a
Constellation Brands to Report Third Quarter Fiscal 2024 Financial Results; Host Conference Call January 5, 202430.11.2023 22:30:18 CET | Press release
VICTOR, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today it will report financial results for its third quarter ended November 30, 2023, on Friday, January 5, 2024, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Executive Vice President and Chief Financial Officer, Garth Hankinson, at 10:30 a.m. ET, January 5, 2024. The conference call can be accessed by dialing +1-877-407-9121 and entering conference identification number 13742927, beginning at 10:20 a.m. ET. A live, listen-only webcast of the conference call will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the call begins, financial information discussed on the conference call, and reconciliations of reported GAAP financial measures with comparable and other